FDA
-
-
-
-
-
-
-
Algernon Pharmaceuticals changes name to Algernon Health
-
-
-
-
-
-
-
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
-
-
-
-
-
-
-
Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough
-
-
-
-
-
-
-
Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study
-
-
-
-
-
-
-
Allergan (AGN) Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil
-
-
-
-
-
-
-
Establishment Labs Inc. (ESTA) Benefits From Allergan (AGN) Exiting Implant Markets
-
-
-
-
-
-
-
Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19
-
327,357 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

